Cidara Therapeutics Inc (NASDAQ:CDTX) has a beta value of 1.17 and has seen 1.34 million shares traded in the last trading session. The company, currently valued at $1.22B, closed the last trade at $55.32 per share which meant it gained $4.79 on the day or 9.47% during that session. The CDTX stock price is -2.73% off its 52-week high price of $56.83 and 81.67% above the 52-week low of $10.14. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.9 million shares traded. The 3-month trading volume is 571.00K shares.
The consensus among analysts is that Cidara Therapeutics Inc (CDTX) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight.
Cidara Therapeutics Inc (NASDAQ:CDTX) trade information
Sporting 9.47% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the CDTX stock price touched $55.32 or saw a rise of 0.77%. Year-to-date, Cidara Therapeutics Inc shares have moved 388.69%, while the 5-day performance has seen it change 14.53%. Over the past 30 days, the shares of Cidara Therapeutics Inc (NASDAQ:CDTX) have changed 113.34%. Short interest in the company has seen 0.65 million shares shorted with days to cover at 3.1.
Wall Street analysts have a consensus price target for the stock at $57.5, which means that the shares’ value could jump 3.79% from current levels. The projected low price target is $46.0 while the price target rests at a high of $69.0. In that case, then, we find that the current price level is -24.73% off the targeted high while a plunge would see the stock lose 16.85% from current levels.
Cidara Therapeutics Inc (CDTX) estimates and forecasts
The company’s shares have gained 122.35% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 1.30% over the past 5 years. Earnings growth for 2025 is a modest 71.53% while over the next 5 years, the company’s earnings are expected to increase by 36.71%.
CDTX Dividends
Cidara Therapeutics Inc is expected to release its next earnings report on 2025-May-08 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Cidara Therapeutics Inc (NASDAQ:CDTX)’s Major holders
Insiders own 1.12% of the company shares, while shares held by institutions stand at 55.45% with a share float percentage of 56.07%. Investors are also buoyed by the number of investors in a company, with Cidara Therapeutics Inc having a total of 58.0 institutions that hold shares in the company. The top two institutional holders are MONASHEE INVESTMENT MANAGEMENT LLC with over 0.37 million shares worth more than $4.41 million. As of 2024-06-30, MONASHEE INVESTMENT MANAGEMENT LLC held 8.0876% of shares outstanding.
The other major institutional holder is BVF INC/IL, with the holding of over 0.34 million shares as of 2024-06-30. The firm’s total holdings are worth over $4.1 million and represent 7.5169% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . As of Mar 31, 2025 , the former fund manager holds about 1.95% shares in the company for having 417.12 shares of worth $23.07 million while later fund manager owns 82.47 shares of worth $4.56 million as of Mar 31, 2025 , which makes it owner of about 0.39% of company’s outstanding stock.
